Portage Biotech Stock Surges As It Prepares For Human Trial

Portage Biotech Inc. (NASDAQ:PRTG) stock traded higher on Monday, with a session volume of 4.49 million compared to the average of 1.2 million, according to data from Benzinga Pro.

On Monday, the company reported confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor.

The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting.

The new data in a murine mesothelioma model demonstrated single-agent activity for PORT-7, which was superior to treatment with a single-agent anti-PD1 antibody.

Also Read: What’s Going On With Portage Biotech Shares Tuesday?

Moreover, the combination of PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone.

Immunohistochemistry of the tumors revealed the formation of tertiary lymphoid structures in the mice receiving the combination.

This indication of a favorable immune response was accompanied by increases in immune effector cells in mice treated with the combination. Mesothelioma is an aggressive and rare type of cancer that affects the mesothelium, a thin layer of tissue lining internal organs like the lungs, abdomen, and heart.

Portage is making preparations to commence a first-in-human clinical trial with PORT-7.

In parallel, Portage is advancing the dose escalation of PORT-6, a potent and selective inhibitor of the A2A adenosine receptor.

Portage plans to ultimately co-administer PORT-6 with PORT-7 in the ongoing ADPORT-601 trial.

The company says this will mark the first time two highly selective A2A and A2B antagonists are combined in patients to achieve a complete blockade of adenosine-induced immunosuppression in the tumor microenvironment.

Portage Biotech presented new preclinical data for PORT-7 (TT-4) at the 2025 European Lung Cancer Congress in March.

The new data demonstrate both single-agent activity for PORT-7 and a dramatic >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine mesothelioma animal model.

Price Action: PRTG stock is up 42.3% at $12.03 during the premarket session at the last check Monday.

Read Next:

• China Accounts Smaller Share In Nike Sales Compared To Pre-Pandemic Levels, But Tariff Pressure Still Persists: Analyst